Organisation paid for research Program year 2025 Source: CMS Open Payments

Washington University

Neither a doctor nor a teaching hospital

Research payments

$264,316,170

19,309 payments

Through program year 2025, Washington University is reported as receiving $264,316,170 in research payments, across 19,309 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$40,186,869	4,107
2024	Research	$34,578,958	3,149
2023	Research	$46,280,862	2,663
2022	Research	$35,226,031	2,194
2021	Research	$31,593,543	2,165
2020	Research	$37,518,122	2,424
2019	Research	$38,931,785	2,607

Breakdown

Who paid Research payments · program years 2019–2025

F. Hoffmann-La Roche AG $30,978,668 375 payments
Genentech, Inc. $24,374,950 876 payments
Pfizer Inc. $24,218,623 725 payments
Eli Lilly and Company $15,987,116 278 payments
Amgen Inc. $12,918,197 144 payments
E.R. Squibb & Sons, L.L.C. $11,065,498 222 payments
Eisai Inc. $8,410,995 505 payments
Merck Sharp & Dohme Corporation $8,227,659 326 payments
Servier BioInnovation $7,495,958 44 payments
Celgene Corporation $7,083,446 125 payments

Studies the money was for Research payments · program years 2019–2025

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in individuals at Risk for and with Dominantly Inherited Alzheimer's Disease $17,340,042 13 payments
Full A Phase 2 Clinical Study Assessing the Safety of An Alternative Dosing Schedule of Palbociclib $10,955,444 44 payments
Dian Tu 002 $8,076,872 7 payments
A Phase II clinical trial of Ivosidenib for patients with clonal hematopoiesis mutations in IDH1a $7,418,061 15 payments
A Pilot Study of Ivosidenib for Patients with Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 $7,055,464 10 payments
A Phase Iiiii Randomized Double-Blind Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease $6,652,362 4 payments
A Phase Iiiii Randomized, Double-Blind, Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease $3,817,062 1 payment
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression $3,108,665 29 payments
AMG 510 - Adv. KRAS G12C solid tumors_20190135 $2,886,039 10 payments
Measurable Residual Diseaseguided Posttransplant Elranatamab Maintenance $2,858,379 15 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $2,194,163 843 payments
Other $1,925,143 142 payments
Non-patient care $199,395 27 payments
Professional salary support $192,529 403 payments
Medical research writing or publication $32,128 2 payments
Overhead $20,254 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.